Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2024 01:00 ET | Source: Addex Therapeutics

Addex to Present at the Swiss Equities Baader Conference

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
January 05, 2024 01:30 ET | Source: Addex Therapeutics

Addex to Present at Biotech Showcase™ 2024

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
December 20, 2023 01:00 ET | Source: Addex Therapeutics

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
December 14, 2023 01:00 ET | Source: Addex Therapeutics

Addex Creates Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
November 29, 2023 01:00 ET | Source: Addex Therapeutics

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024mGlu2 NAM cognition program receives a €4 million Eurostars grantCHF 4.8M ($5.2M)...
November 28, 2023 01:00 ET | Source: Addex Therapeutics

Addex Convenes Extraordinary General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
November 23, 2023 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
November 14, 2023 01:00 ET | Source: Addex Therapeutics

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
November 08, 2023 01:00 ET | Source: Addex Therapeutics

Addex Regains Nasdaq Listing Compliance

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
November 02, 2023 02:00 ET | Source: Addex Therapeutics

Addex Announces Participation in the Bio-Europe 2023 Conference

Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...